Compugen (NASDAQ:CGEN) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of Compugen (NASDAQ:CGEN) from a hold rating to a buy rating in a research note issued to investors on Thursday.

Separately, Truist Financial lowered their price target on Compugen from $5.00 to $4.00 and set a buy rating on the stock in a research report on Tuesday, May 21st.

Compugen Stock Performance

NASDAQ:CGEN opened at $1.68 on Thursday. The stock has a market cap of $145.52 million, a price-to-earnings ratio of -8.84 and a beta of 2.71. Compugen has a 1 year low of $0.53 and a 1 year high of $3.03. The business has a fifty day moving average of $2.05 and a 200-day moving average of $2.14.

Compugen (NASDAQ:CGEN) last announced its earnings results on Monday, May 20th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. The company had revenue of $2.56 million during the quarter, compared to the consensus estimate of $2.79 million. On average, equities research analysts predict that Compugen will post 0.05 EPS for the current year.

Institutional Investors Weigh In On Compugen

A hedge fund recently bought a new stake in Compugen stock. Heron Bay Capital Management bought a new position in Compugen Ltd. (NASDAQ:CGEN) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 12,547 shares of the biotechnology company’s stock, valued at approximately $32,000. 12.22% of the stock is currently owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.